Actively Recruiting
99mTc-P137 SPECT/CT in Prostate Cancer
Led by First Affiliated Hospital Xi'an Jiaotong University · Updated on 2023-02-23
40
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Purpose: This study will take prostate specific membrane antigen (PSMA) as the targeting of radionuclide labeled molecular probe to explore the diagnostic efficacy of 99mTc-P137 radioactive probe in prostate cancer. Combining with SPECT/CT to optimize the imaging, image analysis and clinical diagnosis process of 99mTc-P137 probe, the aim of the study is to provide new methods and new means for the early detection, early diagnosis, accurate tumor staging, treatment decision and prognosis judgment of malignant tumor, and will provide scientific and clinical basis for the precise diagnosis and treatment of prostate cancer. Research objectives: To investigate the clinical translational application value of 99mTc-P137 molecular probe in accurate detection of prostate cancer lesions. Research design: A prospective study design will be used in this study. Patients meeting the inclusion criteria of this study will be analyzed with 99mTc-P137 SPECT/CT imaging. To evaluate the diagnostic and prognostic value of 99mTc-P137 nuclear medicine imaging in accurate detection of prostate cancer lesions, clinical surgical specimens and pathological diagnosis will be used as the gold standard. Study the population Indications: For patients with suspected prostate cancer who plan to undergo surgical resection or puncture biopsy after various examinations, the final pathological results can be obtained.
CONDITIONS
Official Title
99mTc-P137 SPECT/CT in Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Highly suspicious for prostate cancer based on any of the following: significant change in serum PSA levels (PSA <4.0 ng/mL with annual change >0.35 ng/mL or PSA >4.0 ng/mL with annual change >0.75 ng/mL), or first or second degree relatives with a history of prostate cancer, or MRI PI-RADS score 3 or above
- Prostate biopsy or surgical pathology diagnosis of prostate cancer
- Able to provide clinical laboratory results (blood routine, biochemical, serum PSA) within one month before the study
- Have at least two imaging exams including CT, MRI, nuclear medicine (PET/CT or SPECT/CT), ultrasound, or other imaging techniques
- Able to complete the inspection independently
- Voluntary and signed informed consent
You will not qualify if you...
- History of other malignant tumors
- Severe liver or kidney damage
- Unable to obtain pathology or long-term follow-up results
- Lack of access to relevant reference imaging and clinical data
- Difficulty cooperating with the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710061
Actively Recruiting
Research Team
R
Rui Gao
CONTACT
X
Xinru Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here